UniQure

Impact: UniQure developed the experimental gene therapy AMT-130, which has shown significant success in slowing Huntington s disease progression, leading to a substantial increase in its stock price.

Impact: UniQure is the defendant in a securities fraud class action lawsuit due to alleged material misstatements and omissions regarding its Huntington's disease gene therapy drug, AMT-130, which led to a significant drop in its share price.

Impact: UniQure is facing a securities class action lawsuit and severe public criticism from the United States — Food and Drug Administration regarding its gene therapy candidate, AMT-130, leading to a significant drop in its stock price.

Impact: UniQure is facing a securities class action lawsuit for allegedly misrepresenting its interactions with the United States — Food and Drug Administration regarding its gene therapy candidate AMT-130, leading to a significant drop in its stock price.

Impact: UniQure is facing a class action lawsuit for allegedly making false and misleading statements regarding the FDA approval of its Pivotal Study and the potential delay in its Biologics License Application timeline.

Impact: UniQure will report its first quarter 2026 financial results and host a conference call to discuss them, which is a routine financial disclosure for the company.

Impact: UniQure is an accounting advisory firm that partners with Numero AI, benefiting from the expanded capabilities post-acquisition.